The Carlos III Health Institute (ISCIII) has identified the first cases of a Respiratory Syncytial Virus (RSV) variant resistant to nirsevimab, the breakthrough monoclonal antibody used to prevent bronchiolitis in infants. While the drug remains globally effective, this discovery highlights the virus's evolutionary capacity and the critical need for constant genomic surveillance to protect the youngest patients.
The Respiratory Syncytial Virus (RSV) has displaced influenza as the leading cause of hospitalizations among children in Argentina. With over 65,000 bronchiolitis cases and 2,267 hospitalizations reported, experts are calling for a combined nationwide strategy.
According to the latest National Epidemiological Bulletin, Respiratory Syncytial Virus (RSV) has become the main agent detected in hospitalized patients, displacing influenza and severely affecting babies under one year old. With over 65,000 bronchiolitis cases in 2026 so far, specialists highlight prevention tools like the maternal vaccine and nirsevimab to safeguard infants.
Respiratory Syncytial Virus (RSV) has overtaken influenza as the leading cause of severe respiratory hospitalizations in Argentina. With over 65,000 bronchiolitis cases and 2,267 RSV-related hospitalizations reported in 2026, health authorities are focusing on protecting vulnerable infants.
